In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $21.00. The company’s shares closed last Monday at $20.71, close to its 52-week low of $15.64.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -3.3% and a 38.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $29.11.
Based on Nektar Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $98.81 million. In comparison, last year the company had a GAAP net loss of $96.14 million.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NKTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments.